In pursuance of Regulation 30 and Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board of Directors at ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.7 pts less than Nifty Microcap 250 and 8.3 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved unaudited financial results for Q3 and nine months ended December 31, 2025. Revenue from operations grew modestly to Rs. 911.13 lakhs in Q3 (vs Rs. 882.84 lakhs in Q3 FY25), and to Rs. 2,722.85 lakhs for nine months (vs Rs. 2,565.06 lakhs), about 6% YoY growth. Despite this top-line growth, the company reported a net loss of Rs. 54.06 lakhs for Q3 and Rs. 108.75 lakhs for nine months, although losses are narrower than the prior year (Rs. 62.95 lakhs and Rs. 168.66 lakhs respectively). Reserves remain deeply negative at Rs. (935.62) lakhs. The statutory auditors issued an unmodified limited review report with no qualifications.
Shareholders should note that despite revenue growth, the company continues to post losses and carries negative reserves, signalling accumulated past losses. However, the narrowing of losses year-on-year is a mild positive. Stock price reaction may be muted given the persistent unprofitability.